Payment overview · 2025
General Payments
$221,336.56
313 reported records · 34 companies
Healthcare provider profile · identity verified
Ruth Kellum Fredericks, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · JACKSON, MS · NPI 1730138843
Verified facts
What the public records show
CMS Open Payments records show Ruth Kellum Fredericks, M.D. received $221,336.56 in general payments during 2025 across 313 reported records.
EMD Serono, Inc. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Eliquis, Jardiance, Mavenclad, Nuplazid, Nurtec Odt, Qulipta, Tysabri, Ubrelvy, Ultomiris, Vumerity, Vyvgart Hytrulo, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nuplazid by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vyvgart Hytrulo by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Soliris by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ultomiris by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Vumerity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Zeposia by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mavenclad as an associated drug or biological on 3542 records involving 766 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mavenclad by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ocrevus as an associated drug or biological on 3064 records involving 1133 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ocrevus by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Panzyga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $78,259.73 | 35.4% | 52 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66,890.61 | 30.2% | 36 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18,349.55 | 8.3% | 25 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $18,327.75 | 8.3% | 24 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17,138.67 | 7.7% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16,723.30 | 7.6% | 23 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3,056.63 | 1.4% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $355.74 | 0.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $280.09 | 0.1% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.90 | 0.1% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $198.62 | 0.1% | 13 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $190.46 | 0.1% | 9 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $148.29 | 0.1% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $142.17 | 0.1% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $134.66 | 0.1% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$91.41 | 0.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.95 | 0.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $88.79 | 0.0% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $68.17 | 0.0% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $67.32 | 0.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $56.20 | 0.0% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $55.75 | 0.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.09 | 0.0% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.23 | 0.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.66 | 0.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.57 | 0.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.94 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.24 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.49 | 0.0% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $18.40 | 0.0% | 1 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $17.83 | 0.0% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.09 | 0.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.05 | 0.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $187,200.00 | 55 |
| Travel and Lodging | $22,056.43 | 36 |
| Food and Beverage | $7,276.63 | 217 |
| Honoraria | $2,762.50 | 2 |
| Consulting Fee | $2,041.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $66,890.61 | 36 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $66,066.33 | 36 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $18,349.55 | 25 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $16,777.05 | 13 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $16,680.79 | 12 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14,669.63 | 19 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $3,056.63 | 18 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $453.20 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $355.74 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $300.70 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $280.09 | 19 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $265.71 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $198.62 | 13 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $190.46 | 9 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $148.29 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.73 | 12 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $134.66 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $127.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.02 | 9 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $90.95 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $89.52 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $88.79 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $85.17 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $55.75 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $54.09 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $48.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $31.94 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $31.54 | 2 | 2025 |
Source payment records
|
|||||
| REYVOW Normalized: reyvow |
Drug | Lilly USA, LLC | $31.54 | 2 | 2025 |
Source payment records
|
|||||
| SOLITAIRE X Normalized: solitaire x |
Device | Medtronic, Inc. | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 339 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mavenclad mavenclad |
2025 | Mavenclad | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 49 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 59 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
339 | 69 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Mavenclad open payments reported associated product |
CMS Open Payments — General Payments 3542 supporting records · 766 recipient NPIs · example record 1236867010 |
Mavenclad · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Ocrevus open payments reported associated product |
CMS Open Payments — General Payments 3064 supporting records · 1133 recipient NPIs · example record 1211488404 |
Ocrevus · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
339 | 69 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1433 | 304 |
| Donepezil Hcl | Donepezil Hcl | 749 | 183 |
| Memantine Hcl | Memantine Hcl | 736 | 163 |
| Levetiracetam | Levetiracetam | 623 | 137 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 592 | 139 |
| Duloxetine Hcl | Duloxetine Hcl | 567 | 134 |
| Escitalopram Oxalate | Escitalopram Oxalate | 522 | 139 |
| Topiramate | Topiramate | 451 | 112 |
| Baclofen | Baclofen | 439 | 96 |
| Alprazolam | Alprazolam | 424 | 94 |
| Trazodone Hcl | Trazodone Hcl | 405 | 111 |
| Primidone | Primidone | 395 | 89 |
| Clonazepam | Clonazepam | 394 | 76 |
| Tizanidine Hcl | Tizanidine Hcl | 375 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 356 | 63 |
| Eliquis | Apixaban | 339 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 334 | 89 |
| Pregabalin | Pregabalin | 328 | 71 |
| Fluoxetine Hcl | Fluoxetine Hcl | 327 | 62 |
| Sertraline Hcl | Sertraline Hcl | 325 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 86 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 317 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 68 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 276 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 227 | 69 |
| Quetiapine Fumarate | Quetiapine Fumarate | 210 | 45 |
| Sodium Chloride | 0.9 % Sodium Chloride | 208 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 200 | 53 |
| Folic Acid | Folic Acid | 197 | 57 |
| Temazepam | Temazepam | 191 | 38 |
| Methocarbamol | Methocarbamol | 190 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 182 | 49 |
| Omeprazole | Omeprazole | 179 | 50 |
| Diazepam | Diazepam | 177 | 50 |
| Zonisamide | Zonisamide | 177 | 40 |
| Carbamazepine | Carbamazepine | 163 | 38 |
| Bupropion Xl | Bupropion Hcl | 162 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 36 |
| Propranolol Hcl | Propranolol Hcl | 156 | 42 |
| Buspirone Hcl | Buspirone Hcl | 152 | 33 |
| Naratriptan Hcl | Naratriptan Hcl | 151 | 44 |
| Acetazolamide | Acetazolamide | 149 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 39 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 146 | 27 |
| Lamotrigine | Lamotrigine | 143 | 26 |
| Potassium Chloride | Potassium Chloride | 136 | 32 |
| Meloxicam | Meloxicam | 134 | 44 |
| Tramadol Hcl | Tramadol Hcl | 133 | 35 |
| Dalfampridine Er | Dalfampridine | 132 | 21 |
| Lacosamide | Lacosamide | 127 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 125 | 32 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 121 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 119 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 115 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 114 | 25 |
| Mirtazapine | Mirtazapine | 111 | 21 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 109 | 22 |
| Prednisone | Prednisone | 104 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 101 | 21 |
| Famotidine | Famotidine | 100 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 29 |
| Valacyclovir | Valacyclovir Hcl | 100 | 20 |
| Acetazolamide Er | Acetazolamide | 99 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 92 | 24 |
| Copaxone | Glatiramer Acetate | 90 | 12 |
| Meclizine Hcl | Meclizine Hcl | 88 | 21 |
| Oxcarbazepine | Oxcarbazepine | 87 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 86 | 23 |
| Aimovig Autoinjector | Erenumab-Aooe | 85 | 16 |
| Lorazepam | Lorazepam | 83 | 17 |
| Modafinil | Modafinil | 83 | 18 |
| Nifedipine Er | Nifedipine | 77 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 77 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 13 |
| Nabumetone | Nabumetone | 70 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 12 |
| Tysabri | Natalizumab | 67 | suppressed |
| Vumerity | Diroximel Fumarate | 66 | suppressed |
| Briviact | Brivaracetam | 65 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 18 |
| Eszopiclone | Eszopiclone | 61 | 14 |
| Teriflunomide | Teriflunomide | 61 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 11 |
| Zaleplon | Zaleplon | 60 | 23 |
| Qulipta | Atogepant | 59 | 16 |
| Glatiramer Acetate | Glatiramer Acetate | 57 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 20 |
| Neupro | Rotigotine | 55 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 55 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 53 | 26 |
| Atenolol | Atenolol | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | 16 |
| Lisinopril | Lisinopril | 51 | 17 |
| Tecfidera | Dimethyl Fumarate | 51 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 50 | 11 |
| Celecoxib | Celecoxib | 50 | 16 |
| Furosemide | Furosemide | 50 | 17 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 50 | suppressed |
| Ultomiris | Ravulizumab-Cwvz | 50 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 49 | 17 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 14 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 11 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 45 | suppressed |
| Carbamazepine Er | Carbamazepine | 44 | 11 |
| Avonex (4 Pack) | Interferon Beta-1a | 43 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 43 | 23 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 40 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 20 |
| Irbesartan | Irbesartan | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Dexamethasone | Dexamethasone | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 24 |
| Austedo | Deutetrabenazine | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | 13 |
| Rebif | Interferon Beta-1a/Albumin | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 31 | suppressed |
| Ocrevus | Ocrelizumab | 31 | 16 |
| Entacapone | Entacapone | 30 | suppressed |
| Glatopa | Glatiramer Acetate | 30 | suppressed |
| Ubrelvy | Ubrogepant | 30 | suppressed |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 17 |
| Carbatrol | Carbamazepine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 25 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 24 | suppressed |
| Ampyra | Dalfampridine | 23 | suppressed |
| Betaseron | Interferon Beta-1b | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Armodafinil | Armodafinil | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 18 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Aubagio | Teriflunomide | 21 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 21 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Riluzole | Riluzole | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Soliris | Eculizumab | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Mavenclad | Cladribine | 16 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Tegretol Xr | Carbamazepine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 12 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221,336.56 · 313 records | EMD Serono, Inc. | ACTHAR, AJOVY, AMVUTTRA, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CAPLYTA, ELIQUIS, EMGALITY, EPIDIOLEX, FYCOMPA, Fintepla, HYQVIA, INGREZZA, JARDIANCE, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, POCKET EEG DEVICE, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, REYVOW, SKYCLARYS, SOLITAIRE X, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WATCHMAN Access System, WaveWriter Alpha Prime 16, ZAVZPRET, ZEPOSIA | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error